Abstract:COPD is a common, preventable and treatable airway disease, and is currently the third leading cause of death worldwide. About one billion people worldwide are estimated to have vitamin D deficiency or insufficiency. Vitamin D deficiency is common among people with COPD, and has been reported to be associated with reduced lung function and increased risk of acute exacerbations of COPD. Several clinical trials of vitamin D to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and improve COPD control have been conducted, but an up‐to‐date meta‐analysis of all double‐blind, randomised, placebo‐controlled trials of this intervention is lacking. To assess the effects of vitamin D for the management of acute exacerbations and symptoms for people with COPD. We searched the Cochrane Airways Trials Register and reference lists of articles. We also searched trial registries directly, and contacted the authors of studies in order to identify additional trials. The date of the last search was 24 August 2022. We included double‐blind, randomised, placebo‐controlled trials of vitamin D or its hydroxylated metabolites, for adults with a clinical diagnosis of chronic obstructive pulmonary disease based on the presence of characteristic symptoms and irreversible airflow obstruction. We did not impose restrictions regarding disease severity or baseline vitamin D status, in order to maximise generalisability. We used standard Cochrane methods. The primary outcome was the rate of moderate or severe exacerbations (requiring systemic corticosteroids, antibiotics or both). We also performed subgroup analyses to determine whether the effect of vitamin D on the rate of moderate or severe exacerbations was modified by baseline vitamin D status, COPD severity or regular inhaled corticosteroid use. The main secondary outcomes of interest were the proportion of participants experiencing one or more exacerbations (moderate or severe), the change in forced expiratory volume in one second (FEV1, % predicted) and the proportion of participants with one or more serious adverse events of any cause, mortality (all‐cause) and quality of life. We used GRADE to assess the certainty of evidence for each outcome. We included 10 double‐blind, randomised, placebo‐controlled trials in this review, involving a total of 1372 adults. Five studies contributed to the primary outcome analysis of the rate of moderate or severe exacerbations requiring systemic corticosteroids, antibiotics or both. The duration of studies ranged from six weeks to 40 months, and all investigated the effects of administering cholecalciferol (vitamin D 3 ). One study included two intervention arms, one where vitamin D 3 was given and one where calcitriol (1,25‐dihydroxyvitamin D) was given. The majority of participants had mild to moderate COPD, and profound vitamin D deficiency (25‐hydroxyvitamin D (25(OH)D) < 25 nmol/L) at baseline was rare (123 participants contributing data to subgroup analysis). Administration of vitamin D or its hydroxylated metabolites results in little to no change in the overall rate of exacerbations requiring systemic corticosteroids, antibiotics or both (rate ratio (RR) 0.98, 95% CI 0.86 to 1.11; 5 studies, 980 participants; high‐certainty evidence). Vitamin D supplementation did not influence any meta‐analysed secondary outcomes. These were all based on moderate‐ or high‐certainty evidence aside from adverse events and quality of life, which were based on low‐certainty evidence. We observed little to no change in the proportion of participants experiencing one or more moderate or severe exacerbations (odds ratio (OR) 0.94, 95% CI 0.72 to 1.24; 5 studies, 980 participants; high‐certainty evidence). Additionally, vitamin D probably results in little to no difference in the inter‐arm mean change in FEV1 (% predicted) (mean difference 2.82 higher in intervention arm, 95% CI ‐2.42 to 8.06; 7 studies, 1063 participants; moderate‐certainty evidence). There was also probably no effect of vitamin D on the incidence of serious adverse events due to any cause; although we identified an anticipated absolute effect of 36 additional adverse events per 1000 people, the confidence interval included the null hypothesis of no effect (OR 1.19, 95% CI 0.82 to 1.71; 5 studies, 663 participants; moderate‐certainty evidence). Vitamin D may have little to no effect on mortality (OR 1.13, 95% CI 0.57 to 2.21; 6 studies, 1019 participants; low‐certainty evidence). It also may have little to no effect on quality of life as measured by validated instruments (narrative findings; 5 studies, 663 participants; low‐certainty evidence). We assessed one study as being at high risk of bias in at least one domain; this did not contribute data to the meta‐analysis of the primary outcome reported above. Sensitivity analysis that excluded this study from the meta‐analysed outcome -Abstract Truncated-

Effect of Vitamin A on the Cytokines Expression of COPD Patients in Stable Stage

Effects of Vitamin D on Respiratory Function and Immune Status for Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis

The correlation between a Th1/Th2 cytokines imbalance and vitamin D level in patients with early chronic obstructive pulmonary disease (COPD), based on screening results

Effects of Vitamin A on Airway Inflammatory Cells and TNF-a of Lung Tissue in Rats with Asthma

Efficacy of vitamin D supplementation on COPD and asthma control: A systematic review and meta-analysis

Correlation Between Vitamin D, Inflammatory Markers, and T Lymphocytes With the Severity of Chronic Obstructive Pulmonary Disease and its Effect on the Risk of Acute Exacerbation: A Single Cross-sectional Study

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Changes of Metailoproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Interleukin-8 in Elderly Patients with Chronic Obstructive Pulmonary Disease and the Effects of Different Drugs

Research of the Effect of 1,25-Dihydroxyvitamin D3 on Inflammation in Rats with Chronic Obstruction Pulmonary Disease

Efficacy of Symbicort in treatment of CVA patients and its effect on cytokine levels and small airway function

The Observation of Rosuvastatin Affect on IL-8 and the Quality of Life on COPD Patients

Relationship between Vitamin D Level and Serum TNF-α Concentration on the Severity of Chronic Obstructive Pulmonary Disease

Effect of Mannatide Capsules in Treating Stable Stage of Chronic Obstructive Pulmonary Disease

Effect of Ulinastatin on TNF-α、IL-6 and SOD in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Vitamin D for the management of chronic obstructive pulmonary disease

Effect of Immunmmodulatory Strategy on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

The Study of T Cells, IgA, IgG and Other Immune Function Situations in Patients with Chronic Obstructive Pulmonary Disease

Change of Serum Inflammatory Cytokines Levels in Patients With Chronic Obstructive Pulmonary Disease, Pneumonia and Lung Cancer

Effect of Virus Infections on the Airway Inflammation in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Clinical value of Vitamin-D combined with budesonide/formoterol and theophylline sodium glycinate sustained-release tablets in the treatment of chronic obstructive pulmonary disease patients

Effect of ultrashort wave therapy on cytokine changes in patients with chronic obstructive pulmonary disease